A: A DaTscan® is the trademark name for I-123 Ioflupane. This radiopharmaceutical agent (approved by the FDA on January 14, 2011) is used in conjunction with Single Photon Emission Computed Tomography (SPECT) imaging to evaluate patients with suspected Parkinsonian syndromes. I-123 Ioflupane is used to determine the location and concentration of dopamine transporters (DaTs) in the synapses of striatal dopaminergic neurons. It is effective in detecting degeneration of the dopaminergic nigrostriatal pathway, thus differentiating patients with essential tremor from those with presynaptic Parkinsonian syndromes. In some cases, it may assist in distinguishing between some causes of Parkinsonism. I-123 Ioflupane is administered intravenously and SPECT images of the brain are obtained 3-6 hours after injection.
CPT code 78607 [Brain imaging, tomographic (SPECT)] is used to report the SPECT images of the brain, and the HCPCS Level II code A9584 (Iodine I-123 Ioflupane, diagnostic, per study dose, up to 5 millicuries) is used to report the I-123 radiopharmaceutical administered.